Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer.
Fiche publication
Date publication
décembre 2015
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DOLIVET Gilles, Dr LEROUX Agnès, Dr MASTRONICOLA Romina
Tous les auteurs :
Schilling C, Stoeckli SJ, Haerle SK, Broglie MA, Huber GF, Sorensen JA, Bakholdt V, Krogdahl A, von Buchwald C, Bilde A, Sebbesen LR, Odell E, Gurney B, O'Doherty M, de Bree R, Bloemena E, Flach GB, Villarreal PM, Fresno Forcelledo MF, Junquera Gutiérrez LM, Amézaga JA, Barbier L, Santamaría-Zuazua J, Moreira A, Jacome M, Vigili MG, Rahimi S, Tartaglione G, Lawson G, Nollevaux MC, Grandi C, Donner D, Bragantini E, Dequanter D, Lothaire P, Poli T, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, McGurk M
Lien Pubmed
Résumé
Optimum management of the N0 neck is unresolved in oral cancer. Sentinel node biopsy (SNB) can reliably detect microscopic lymph node metastasis. The object of this study was to establish whether the technique was both reliable in staging the N0 neck and a safe oncological procedure in patients with early-stage oral squamous cell carcinoma.
Mots clés
Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, mortality, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Europe, False Negative Reactions, Female, Head and Neck Neoplasms, mortality, Humans, Kaplan-Meier Estimate, Lymph Nodes, pathology, Lymphatic Metastasis, Male, Middle Aged, Mouth Neoplasms, mortality, Neck Dissection, Neoplasm Micrometastasis, Neoplasm Staging, Predictive Value of Tests, Proportional Hazards Models, Prospective Studies, Radiotherapy, Adjuvant, Risk Factors, Sentinel Lymph Node Biopsy, adverse effects, Time Factors, Treatment Outcome
Référence
Eur. J. Cancer. 2015 Dec;51(18):2777-84